Active Ingredient History
Entinostat, also known as SNDX-275 and MS-275, is a benzamide histone deacetylase inhibitor undergoing clinical trials for treatment of various cancers. Wikipedia
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Alphapapillomavirus (Phase 1/Phase 2)
Anemia, Refractory (Phase 2)
Anus Neoplasms (Phase 1/Phase 2)
Brain Neoplasms (Phase 1)
Brain Stem Neoplasms (Phase 1)
Breast Diseases (Phase 1)
Breast Neoplasms (Phase 3)
Breast Neoplasms, Male (Phase 2)
Bronchial Neoplasms (Phase 1)
Burkitt Lymphoma (Phase 1)
Carcinoma, Non-Small-Cell Lung (Phase 2)
Carcinoma, Ovarian Epithelial (Phase 1/Phase 2)
Carcinoma, Renal Cell (Phase 2)
Cholangiocarcinoma (Phase 2)
Colonic Neoplasms (Phase 2)
Colorectal Neoplasms (Phase 2)
Digestive System Neoplasms (Phase 1)
Drug Interactions (Phase 1)
Endocrine Gland Neoplasms (Phase 1)
Endometrial Neoplasms (Phase 2)
Epigenetic Repression (Phase 2)
Esophageal Neoplasms (Phase 1/Phase 2)
Fallopian Tube Neoplasms (Phase 1/Phase 2)
Glioma (Phase 1)
Hamartoma (Phase 1/Phase 2)
Head and Neck Neoplasms (Phase 1/Phase 2)
Healthy Volunteers (Phase 1)
Hodgkin Disease (Phase 2)
Human papillomavirus 16 (Phase 1/Phase 2)
Intraocular Lymphoma (Phase 1)
Kidney Failure, Chronic (Phase 1)
Kidney Neoplasms (Phase 1/Phase 2)
Leukemia (Phase 1)
Leukemia, Eosinophilic, Acute (Phase 1)
Leukemia, Lymphocytic, Chronic, B-Cell (Phase 1)
Leukemia-Lymphoma, Adult T-Cell (Phase 1)
Leukemia, Monocytic, Acute (Phase 2)
Leukemia, Myelogenous, Chronic, BCR-ABL Positive (Phase 1/Phase 2)
Leukemia, Myeloid, Acute (Phase 2)
Leukemia, Myeloid, Chronic-Phase (Phase 1)
Leukemia, Myelomonocytic, Acute (Phase 2)
Leukemia, Myelomonocytic, Chronic (Phase 2)
Lung Diseases (Phase 1)
Lung Neoplasms (Phase 1)
Lymphoma (Phase 2)
Lymphoma, B-Cell, Marginal Zone (Phase 1)
Lymphoma, Follicular (Phase 1)
Lymphoma, Large B-Cell, Diffuse (Phase 1)
Lymphoma, Large-Cell, Anaplastic (Phase 1)
Lymphoma, Large-Cell, Immunoblastic (Phase 1)
Lymphoma, Mantle-Cell (Phase 1)
Lymphoma, Non-Hodgkin (Phase 1/Phase 2)
Lymphoma, T-Cell (Phase 1)
Lymphomatoid Granulomatosis (Phase 1)
Melanoma (Phase 2)
Multiple Myeloma (Phase 1)
Myelodysplastic Syndromes (Phase 2)
Myeloproliferative Disorders (Phase 2)
Neoplasm Metastasis (Phase 2)
Neoplasms (Phase 1/Phase 2)
Neoplasms by Histologic Type (Phase 1)
Neoplasms, Glandular and Epithelial (Phase 1)
Neuroendocrine Tumors (Phase 2)
Oropharyngeal Neoplasms (Phase 1/Phase 2)
Ovarian Diseases (Phase 1/Phase 2)
Ovarian Neoplasms (Phase 1/Phase 2)
Pancreatic Neoplasms (Phase 2)
Penile Neoplasms (Phase 1/Phase 2)
Prostatic Neoplasms (Phase 1)
Respiratory Tract Neoplasms (Phase 1)
Sezary Syndrome (Phase 1)
Small Cell Lung Carcinoma (Phase 1)
Thoracic Neoplasms (Phase 1)
Thrombocytopenia (Phase 2)
Triple Negative Breast Neoplasms (Phase 2)
Urinary Bladder Neoplasms (Phase 2)
Uterine Cervical Neoplasms (Phase 1/Phase 2)
Vaginal Neoplasms (Phase 1/Phase 2)
Volunteers (Phase 1)
Vulvar Neoplasms (Phase 1/Phase 2)
Waldenstrom Macroglobulinemia (Phase 1)
Trial | Phase | Start Date | Organizations | Indications |
---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue